妇科癌症的靶向治疗：临床证据的综合评价。

Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, P.R. China.

Department of Biomedical Sciences, School of Medicine and Health Sciences, University of North Dakota, Grand Forks, ND, 58203, USA.

Signal Transduct Target Ther. 2020 Jul 29;5(1):137. doi: 10.1038/s41392-020-0199-6.

Advanced and recurrent gynecological cancers are associated with poor prognosis and lack of effective treatment. The developments of the molecular mechanisms on cancer progression provide insight into novel targeted therapies, which are emerging as groundbreaking and promising cancer treatment strategies. In gynecologic malignancies, potential therapeutic targeted agents include antiangiogenic agents, poly (ADP-ribose) polymerase (PARP) inhibitors, tumor-intrinsic signaling pathway inhibitors, selective estrogen receptor downregulators, and immune checkpoint inhibitors. In this article, we provide a comprehensive review of the clinical evidence of targeted agents in gynecological cancers and discuss the future implication.

晚期和复发性妇科癌症与预后不良和缺乏有效治疗相关。癌症进展的分子机制的发展为新型靶向治疗提供了深入了解，这些治疗方法正在成为开创性和有前途的癌症治疗策略。在妇科恶性肿瘤中，潜在的治疗靶向药物包括抗血管生成药物、多聚（ADP-核糖）聚合酶（PARP）抑制剂、肿瘤内在信号通路抑制剂、选择性雌激素受体下调剂和免疫检查点抑制剂。本文综述了妇科恶性肿瘤靶向药物的临床证据，并探讨了其未来意义。